“We are excited to highlight the data from our Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. The statistically significant reductions in viral shedding and sustained efficacy 12 months after completion of dosing suggest GEN-003 could become a cornerstone therapy for patients suffering from genital herpes,” said Chip Clark, president and chief executive officer of Genocea. “Additionally, the trends seen in reducing nasopharyngeal colonization in the Phase 2a trial of GEN-004 for the treatment of pneumococcal disease demonstrates the potential of the vaccine’s concept, which we hope will lead to a partnership to advance this program.”
Genocea data to be presented at ASM Microbe 2016 include:
Pneumococcus naturally colonizes the nasopharynx, or nose and throat, as a precursor to infection. Pneumococcus causes non-invasive pneumococcal disease (NIPD) when it spreads from the nasopharynx into the upper and lower respiratory system to cause diseases such as otitis media (ear infection) and non-bacteremic pneumonia. When it enters the bloodstream, pneumococcus can cause invasive pneumococcal disease (IPD), including life-threatening illnesses such as sepsis, meningitis and bacteremic pneumonia.